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Objectives
Efavirenz-based HIV therapy is associated with breast hypertrophy and gynaecomastia. Here, we
tested the hypothesis that efavirenz induces gynaecomastia through direct binding and modulation
of the oestrogen receptor (ER).
Methods
To determine the effect of efavirenz on growth, the oestrogen-dependent, ER-positive breast cancer
cell lines MCF-7, T47D and ZR-75-1 were treated with efavirenz under oestrogen-free conditions in
the presence or absence of the anti-oestrogen ICI 182,780. Cells treated with 17b-oestradiol in the
absence or presence of ICI 182,780 served as positive and negative controls, respectively. Cellular
growth was assayed using the crystal violet staining method and an in vitro receptor binding assay
was used to measure the ER binding affinity of efavirenz.
Results
Efavirenz induced growth in MCF-7 cells with an estimated effective concentration for half-
maximal growth (EC50) of 15.7 mM. This growth was reversed by ICI 182,780. Further, efavirenz
binds directly to the ER [inhibitory concentration for half maximal binding (IC50) of  52mM] at a
roughly 1000-fold higher concentration than observed with 17b-oestradiol.
Conclusions
Our data suggest that efavirenz-induced gynaecomastia may be caused, at least in part, by drug-
induced ER activation in breast tissues.
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Introduction
The introduction of highly active antiretroviral therapy
(HAART) multi-drug combination regimens has consider-
ably improved the prognosis of patients infected with HIV
by reducing AIDS-related morbidity and mortality [1].
However, chronic treatment with these regimens is
associated with multiple adverse effects, nonadherence
and eventually therapy failure [2]. Treatment regimens
containing the nonnucleoside reverse transcriptase inhi-
bitor efavirenz are preferred in treatment-naı̈ve patients
and are widely used in other settings [3]. While efavirenz is
generally well tolerated, concentration-dependent side
effects that impact drug adherence and promote resistance
have been documented [4]. Common adverse effects of
efavirenz include central nervous system symptoms,
occurring in up to 50% of patients [5], but other less
common adverse effects have also been reported. An
increasing number of reports suggest that the use of
HAART, in particular efavirenz-based therapy, is associated
with breast hypertrophy or gynaecomastia [6–11]. While
mechanisms underlying efavirenz-induced gynaecomastia
are not well understood, a number of hypotheses exist,
including a direct oestrogenic effect, induction of an
immune response, or altered steroid hormone metabolism
by cytochrome P450 enzymes. To our knowledge, none of
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these hypotheses has been tested directly. In this study, we
tested whether efavirenz can induce breast cancer cell
growth by binding and modulating oestrogen receptor (ER)
activity. We examined the ability of efavirenz to (a) induce
the growth of the oestrogen-dependent, ER-positive breast
cancer cell lines MCF-7, T47D and ZR-75-1, in the presence
or absence of the pure anti-oestrogen ICI 182,780; and (b)
directly bind the ER using an in vitro fluorescence
polarization-based receptor binding assay.
Materials and methods
Cell lines and culture conditions
17b-oestradiol (E2) was purchased from Sigma-Aldrich Inc.
(St. Louis, MO, USA). Efavirenz and ICI 182,780 were
purchased from Toronto Research Chemical (Toronto, Ontario,
Canada). The ER-positive, oestrogen-dependent breast cancer
cell lines MCF-7, T47D and ZR-75-1 were obtained from the
Tissue Culture Shared Resource at the Lombardi Comprehen-
sive Cancer Center at Georgetown University (Washington,
DC). These cell lines are widely and routinely used for
examinations of the activities of oestrogens and anti-
oestrogens [12,19]. Cells were routinely cultured in modified
Improved Minimum Essential Medium (IMEM) (Biosource
International Inc., Camarillo, CA, USA) with 10% foetal
bovine serum (Valley Biomedical Inc., Winchester, VA, USA),
at 37 1C in a humidified 5% CO2 atmosphere. For growth
assays in oestrogen-free conditions, cells were repeatedly
washed and grown in steroid-depleted medium (phenol red-
free IMEM supplemented with 5% charcoal stripped calf
bovine serum) as previously described [20]. Cells were plated
in steroid-depleted medium at 2  103 cells/well in 96-well
plates (Falcon, Lincoln Park, NJ, USA) and allowed to attach
overnight before treatment with test drugs. Cells in oestrogen-
free conditions were treated with vehicle (0.1% ethanol), E2 or
efavirenz in the presence or absence of the anti-oestrogen ICI
182,780. The relative cell number after 4–6 days of growth
was determined using crystal violet staining and WST cell
proliferation staining (Roche Applied Science, Indianapolis,
IN, USA) as described previously [21].
Receptor binding assay
Fluorescence polarization-based competitive binding
assays were performed to measure the relative binding
affinity of efavirenz for ER-a using a commercially
available kit (P2698; Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s specifications. We have
previously described the use of this assay to evaluate the
relative affinity of ligands for ER-a [19]. Reactions (100 mL)
were carried out in black-wall, low-volume 96-well plates
(6006270; PerkinElmer, Waltham, MA, USA). Following
2 hours of incubation at room temperature, fluorescence
polarization values were obtained using a BMG PolarStar
Omega plate reader (BMG Labtech, Durham, NC, USA).
Statistical analyses and curve fitting
Student’s t-tests were used to compare treatments with
respective controls (SIGMASTAT Version 3.5; Systat Software
Inc., San Jose, CA, USA). Curve fitting and effective
concentration for half-maximal growth (EC50) or binding
(IC50) were determined using GRAPHPAD PRISM Version 4.03
(GraphPad Software, San Diego, CA, USA).
Results
Efavirenz induces breast cancer cell growth
Efavirenz (10mM) induced growth of MCF-7 cells that was
1.2-fold greater than that induced by vehicle treatment
(Fig. 1a; right, solid bar). This effect was blocked by the anti-
oestrogen ICI 182,780 (Fig. 1a; right, chequered bar). As
expected, E2 (10nM) maximally stimulated growth (3.2-
fold) versus the vehicle treatment (Fig. 1a; left, solid bar). ICI
182,780 completely blocked E2-induced growth (Fig. 1a; left,
chequered bar). Efavirenz induced a similar amount of
growth in ZR-75-1 cells following 4 days of treatment (Fig.
1b), and this growth was blocked by ICI 182,780 (data not
shown). However, efavirenz did not stimulate the growth of
T47D cells following 6 days of treatment (Fig. 1b).
The concentration–effect curve for efavirenz-induced
growth in MCF-7 cells is shown in Fig. 1c. Efavirenz-
induced cellular growth was concentration-dependent up
to 10 mM. Growth induced at any concentration was
completely blocked by 1 mM ICI 182,780 (data not shown).
Higher efavirenz concentrations (50 or 100 mM) were
growth inhibitory to MCF-7, T47D and ZR-75-1 cells; this
effect could not be blocked by ICI 182,780 (data not
shown). Although this growth inhibition at high concen-
trations prevented full characterization of the concentra-
tion–effect relationship, we estimated an EC50 of
approximately 15.7 mM using the data obtained for lower
concentrations (1–10 mM).
Efavirenz directly binds ER-a
The affinity of efavirenz binding to the ER relative to that
of E2 was determined using a competitive binding assay
as described in ‘Materials and methods’ section. Efavirenz
bound ER-a at a 41000-fold higher concentration (IC50
of 52 mM) than E2 (IC50 of 16 nM) under these
experimental conditions (Fig. 2).
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Discussion
Reports show that 1.8–8.4% of male patients develop
gynaecomastia with efavirenz treatment [6–11]. However,
the precise mechanism of this adverse effect remains
unknown. Our data suggest that efavirenz-induced gynae-
comastia may be attributable to direct oestrogenic effects
in breast tissues. We demonstrated that efavirenz induced
the growth of the oestrogen-dependent, ER-positive breast
cancer cell lines MCF-7 and ZR-75-1 and that this effect
was completely reversed by the anti-oestrogen ICI 182,780.
We have also provided evidence that efavirenz binds
directly to ER-a. These data provide the first evidence that
efavirenz-induced breast hypertrophy and gynaecomastia
may be attributable in part to the ability of the drug to
directly activate the ER.
Our data are the first to directly demonstrate that
efavirenz binds to ER-a and that it induces cell growth in
an E2-dependent breast cancer model. While efavirenz
induced growth at 105-fold greater concentrations than
E2, it bound ER-a in vitro at much lower concentrations
(only 103-fold greater concentration than E2), consistent
with the hypothesis that efavirenz acts as a weak agonist of
the ER. Further, although efavirenz was much less potent
than E2 in inducing growth (EC50 values of 15.7 mM vs.
5 pM [12]), our findings may be clinically important,
because efavirenz concentrations that induce growth in our
cell model are within the therapeutic plasma concentration
range achieved after daily oral administration of 600 mg
daily (mean steady-state minimum and maximum con-
centrations of 5.6 and 12.9 mM, respectively, with inter-
patient variability ranging from 0.4 to 48 mM) [4,13]. In
addition, given the lipophilicity of efavirenz and thus the
very large volume of distribution, it is likely that the
concentration in breast tissues is much higher than in
plasma. Efavirenz steady-state plasma concentrations in
HIV-infected patients exhibit wide inter-subject variability
because of the effects of genetic polymorphisms and drug















































Treatment time 4 days 6 days 4 days
Fold vs. control ± SD 1.20 ± 0.02 1.06 ± 0.03 1.15 ± 0.07
P -value 0.0006 0.16 0.0068
Fig. 1 MCF-7 cells were grown in oestrogen-free conditions as
described in ‘Materials and methods’. (a) 17b-oestradiol (E2) was
added to a final concentration of 10 nM, and efavirenz was added
to a final concentration of 10 mM. Cells were treated in the ab-
sence (solid bars) or presence (chequered bars) of ICI 182,780 at a
final concentration of 1mM. Bars represent mean 4-day growth
 standard deviation (SD) versus the vehicle-treated control for
experiments in triplicate. (b) Growth induced by 10 mM efavirenz in
breast cancer cell lines. P-values were determined for efavirenz-
treated cells versus vehicle control. (c) Efavirenz was added at
increasing concentrations from 50 nM to 10mM. Points represent
mean 4-day growth  SD versus the vehicle-treated control for
experiments in triplicate.






















Fig. 2 Fluorescence polarization-based oestrogen receptor (ER)-a
binding assays were performed as described in ‘Materials and
methods’. Decreasing polarization (y-axis) represents increased
receptor occupancy by the test compound, 17b-estradiol (& ) or
efavirenz (}). Points represent mean polarization  standard
deviation for experiments in triplicate.
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ER-a binding and MCF-7 growth induction observed in our
study, and that patients with higher efavirenz exposure are
at increased risk for adverse effects [4,13], it is possible that
patients achieving higher plasma concentrations of efavir-
enz are more likely to experience breast hypertrophy and
gynaecomastia.
The fact that efavirenz induces growth in MCF-7 and
ZR-75-1 cells, but not T47D cells, suggests that the
efavirenz-induced growth may be dependent on the
expression of specific ER transcription cofactors. Unique
nuclear receptor cofactor expression is known to play a
role in the transcriptional activity of other clinically used
agents, particularly the selective ER modulator tamoxifen,
which has differing oestrogenic and anti-oestrogenic
activities in different target tissues [14].
We were unable to study the effect of efavirenz at high
concentrations (410mM), because of nonspecific cytotoxi-
city or cytostatic effects. However, the fact that high-dose
efavirenz-induced growth inhibition was not blocked by
the ICI 182,780 suggests that this is unrelated to its
oestrogenic activity. Interestingly, we found that high
concentrations of efavirenz (1–10 mM) could antagonize
growth induced by 5 pM E2, providing additional evidence
that efavirenz indeed acts as a weak or partial agonist of
ER-a (data not shown). However, we could not confirm that
this growth antagonism was specifically attributable to
competition for binding to ER-a with E2.
Our data may have implications beyond the potential
role of efavirenz in gynaecomastia. Evidence exists for an
increased incidence of AIDS-defining and certain non-
AIDS-defining cancers, including breast cancer, in HIV-
infected patients. Generally, HAART use has been shown to
be protective for AIDS-defining cancers, although the
extent of this protection for non-AIDS-defining cancers
seems limited. A recent meta-analysis of the incidence of
non-AIDS-defining cancers in HIV-infected patients sug-
gests that the incidence of breast cancer in these patients
has significantly increased since the implementation of
HAART as standard therapy [15]). Further epidemiological
studies comparing efavirenz-based and non-efavirenz-
based therapies will be needed to rule out the possibility
that the oestrogenic activity of efavirenz may promote
breast cancer. It also remains to be seen whether efavirenz
interferes with endocrine treatment of breast cancer and
contributes to drug resistance.
This study demonstrates that efavirenz directly binds and
activates the ER, providing a plausible mechanistic
explanation for efavirenz-induced gynaecomastia in HIV-
infected patients. Additional indirect support for this
suggestion has been provided by Kegg and Lau [16], who
reported a case of efavirenz-induced gynaecomastia that
was successfully reversed using 20 mg daily tamoxifen.
Tamoxifen has been widely used for the treatment and
prophylaxis of anti-androgen-induced gynaecomastia in
prostate cancer patients with high efficacy and low toxicity
[17,18] in addition to its widespread use as a front-line
therapy for the treatment and prevention of breast cancer.
As multiple antiretroviral drugs are currently available to
treat HIV infection, switching from efavirenz to alternative
antiretroviral drugs may be one potential strategy to
alleviate this adverse effect. However, multiple factors need
to be considered before switching to an alternative therapy.
Based on our in vitro data and evidence from the literature,
tamoxifen and other anti-oestrogens may be useful in the
treatment of efavirenz-induced gynaecomastia. Impor-
tantly, before considering the addition of an anti-oestrogen
to a patient’s treatment regimen, other potential causes of
gynaecomastia should be assessed. A randomized control
trial would be necessary to fully evaluate the utility, and
more importantly tolerability, of anti-oestrogens as a
treatment for efavirenz-induced gynaecomastia.
Acknowledgements
This work was supported in part by the Breast Cancer
Research Foundation (grant N003173) and by the National
Institute of General Medical Sciences, Bethesda, MD (U-01
GM61373, T-32 GM007767 and R-01 GM078501-02).
References
1 Palella FJ Jr, Delaney KM, Moorman AC et al. Declining
morbidity and mortality among patients with advanced human
immunodeficiency virus infection. HIV outpatient study
investigators. N Engl J Med 1998; 338: 853–860.
2 Carr A, Cooper DA. Adverse effects of antiretroviral therapy.
Lancet 2000; 356: 1423–1430.
3 Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment
of adult HIV infection: 2008 recommendations of the
International AIDS Society-USA panel. JAMA 2008; 300:
555–570.
4 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T.
Efavirenz plasma levels can predict treatment failure and central
nervous system side effects in HIV-1-infected patients. AIDS
2001; 15: 71–75.
5 Cespedes MS, Aberg JA. Neuropsychiatric complications of
antiretroviral therapy. Drug Saf 2006; 29: 865–874.
6 Caso JA, Prieto Jde M, Casas E, Sanz J. Gynecomastia without
lipodystrophy syndrome in HIV-infected men treated with
efavirenz. AIDS 2001; 15: 1447–1448.
7 Mercie P, Viallard JF, Thiebaut R et al. Efavirenz-associated
breast hypertrophy in HIV-infection patients. AIDS 2001; 15:
126–129.
606 MJ Sikora et al.
r 2010 British HIV Association HIV Medicine (2010) 11, 603–607
8 Rahim S, Ortiz O, Maslow M, Holzman R. A case-control study
of gynecomastia in HIV-1-infected patients receiving HAART.
AIDS Read 2004; 14: 23–24, 29–32, 35–40.
9 Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in
current clinical practice: a prospective, open-label
observational study. J Acquir Immune Defic Syndr 2004;
35: 492–502.
10 Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J.
Efavirenz-associated gynecomastia: report of five cases and
review of the literature. Breast J 2004; 10: 244–246.
11 Mira JA, Lozano F, Santos J et al. Gynaecomastia in
HIV-infected men on highly active antiretroviral therapy:
association with efavirenz and didanosine treatment.
Antivir Ther 2004; 9: 511–517.
12 Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME,
Rae JM. The androgen metabolite 5alpha-androstane-
3beta,17beta-diol (3betaAdiol) induces breast cancer growth
via estrogen receptor: implications for aromatase inhibitor
resistance. Breast Cancer Res Treat 2009; 115: 289–296.
13 Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz
plasma concentrations in HIV-infected patients: inter- and
intraindividual variability and clinical effects. Ther Drug Monit
2004; 26: 267–270.
14 Dobrzycka KM, Townson SM, Jiang S, Oesterreich S. Estrogen
receptor corepressors – a role in human breast cancer? Endocr
Relat Cancer 2003; 10: 517–536.
15 Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the
incidence of non-AIDS cancers in HIV-infected individuals.
J Acquir Immune Defic Syndr 2009; 52: 611–622.
16 Kegg S, Lau R. Tamoxifen in antiretroviral-associated
gynaecomastia. Int J STD AIDS 2002; 13: 582–583.
17 Perdona S, Autorino R, De Placido S et al. Efficacy of
tamoxifen and radiotherapy for prevention and treatment of
gynaecomastia and breast pain caused by bicalutamide in
prostate cancer: a randomised controlled trial. Lancet Oncol
2005; 6: 295–300.
18 Fradet Y, Egerdie B, Andersen M et al. Tamoxifen as
prophylaxis for prevention of gynaecomastia and breast pain
associated with bicalutamide 150 mg monotherapy in patients
with prostate cancer: a randomised, placebo-controlled,
dose-response study. Eur Urol 2007; 52: 106–114.
19 Johnson MD, Zuo H, Lee KH et al. Pharmacological
characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel
active metabolite of tamoxifen. Breast Cancer Res Treat 2004;
85: 151–159.
20 Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM,
Lippman ME. GREB 1 is a critical regulator of hormone
dependent breast cancer growth. Breast Cancer Res Treat 2005;
92: 141–149.
21 Rae JM, Lippman ME. Evaluation of novel epidermal growth
factor receptor tyrosine kinase inhibitors. Breast Cancer Res
Treat 2004; 83: 99–107.
Efavirenz modulates the oestrogen receptor 607
r 2010 British HIV Association HIV Medicine (2010) 11, 603–607
